YIH
DMAC icon

Y-Intercept (HK)’s DiaMedica Therapeutics DMAC Stock Holding History

Y-Intercept (HK)’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,335
Closed -$50.5K – 1709
2025
Q1 		$50.5K Sell
13,335
-1,638
-11% -$9.37K ﹤0.01% 1130
2024
Q4 		$81.3K Buy
+14,973
New +$70.6K 0.01% 1110

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Y-Intercept (HK)'s DMAC Position: Q2 2025 in Review

Y-Intercept (HK) sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 13,335 shares — an estimated $50.5K sold.

Y-Intercept (HK) first reported a position in DMAC in Q4 2024 and held it in 2 quarters. The position peaked at $81.3K in Q4 2024. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

  • Y-Intercept (HK) reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 13,335 DiaMedica Therapeutics shares in Q2 2025, an estimated $50.5K.
  • Y-Intercept (HK) first reported a position in DiaMedica Therapeutics in Q4 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s DiaMedica Therapeutics position peaked at $81.3K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.